Effect of β2-microglobulin in evaluating the severity and prognosis of brain injury: a clinical study

BMC Neurology

Table 5 The variance analysis of repeated measurements for β2MG and β2MU

	Time point	Group			Machly W	P₁	F		P₂
	Time point	Brain injury group	Conscious disturbance group	Non-conscious disturbance group	Machly W	P₁	Time	Time*group	Time	Time*group
β2MG	Before HBOT After 1st course After 2nd course	2.64 ± 0.79 2.58 ± 0.76 2.14 ± 0.66	2.89 ± 0.88 2.77 ± 0.65 2.59 ± 0.76	2.38 ± 0.48 2.30 ± 0.79 1.73 ± 0.30	0.881	0.091	10.251	0.189	0.000	0.929
β2MU	Before HBOT After 1st course After 2nd course	6.82 ± 20.2 2.07 ± 7.46 0.65 ± 2.09	10.78 ± 20.2 3.36 ± 9.03 1.15 ± 2.64	0.52 ± 0.50 0.15 ± 0.12 0.11 ± 0.03	0.181	0.000	38.000	39.000	0.059	0.026

Continuous variables are expressed as percentage or mean ± standard deviation, and P < 0.05 indicates statistical difference. P1: the p-value for the sphericity test. P2 of β2MG: p-value for the within-subject effect test. P2 of β2MU: p-value for the multivariate test. β2MG: β2-microglobulin, β2MU: urine β2-microglobulin, HBOT Hyperbaric oxygen therapy

ISSN: 1471-2377